RE:RE:RE:RE:RE:NBF report is out On the capital market side, the recent offering we closed in January has afforded us the resources to further support our strategy to enhance our commercial initiatives, R&D development and working capital needs. Additionally, we are devoting more resources to enhance our outreached to the investment community and the deal has allowed us to cultivate new institutional investors who are focused on life sciences and support our strategy.
scarlet1967 wrote:
"People looking at the transcript"
What else should we look at to get some insights, any suggestions?
qwerty22 wrote:
People looking at the transcript, what was the comment Paul made at the end of the call about investor engagement and bringing on new investors (I assumed he was talking about Soleus there)?
Wino115 wrote: BTW, on of THE KEY issues here is that they are not being covered by biotech analysts or oncology analysts. At this point it's only two middling "healthcare" guys which really doesn't amount to much for Canadian analysts and one NASH only analyst. The really need to lean on the Soleus guys (& whomever else bought in to that OO) to ask them to introduce them around to the actual Wall St biotech and oncology analysts that are important and beg them to cover them. I can't imagine Soleus is all that happy with the silent tree falling either.